Jorge Duconge to Genotype
This is a "connection" page, showing publications Jorge Duconge has written about Genotype.
Connection Strength
1.910
-
Duconge J, Cadilla CL, Seip RL, Rua?o G. Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J. 2015 Sep; 34(3):175-7.
Score: 0.458
-
Duconge J, Santiago E, Hernandez-Suarez DF, Moner? M, L?pez-Reyes A, Rosario M, Renta JY, Gonz?lez P, Ileana Fern?ndez-Morales L, Antonio V?lez-Figueroa L, Arce O, Mar?n-Maldonado F, Nu?ez H, Melin K, Scott SA, Rua?o G. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clin Transl Sci. 2021 11; 14(6):2254-2266.
Score: 0.173
-
Reyes-Gonz?lez S, de Las Barreras C, Reynaldo G, Rodr?guez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 08 18; 35(4).
Score: 0.161
-
Claudio-Campos K, Moner?-Paredes M, Hern?ndez E, Renta J, Duconge J. Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation. Pharmacogenomics. 2019 08; 20(12):891-902.
Score: 0.150
-
Claudio-Campos KI, Gonz?lez-Santiago P, Renta JY, Rodr?guez J, Carrasquillo K, Gaedigk A, Roche A, Ducong? J. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics. 2019 01; 20(1):3-8.
Score: 0.143
-
Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nu?ez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int J Environ Res Public Health. 2018 05 30; 15(6).
Score: 0.138
-
Duconge J, Ramos AS, Claudio-Campos K, Rivera-Miranda G, Berm?dez-Bosch L, Renta JY, Cadilla CL, Cruz I, Feliu JF, Vergara C, Rua?o G. A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One. 2016; 11(1):e0145480.
Score: 0.117
-
Valent?n II, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, Rua?o G, Duconge J. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J. 2014 Sep; 33(3):97-104.
Score: 0.107
-
Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Rua?o G, Duconge J. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother. 2012 Feb; 46(2):208-18.
Score: 0.089
-
Rodr?guez-V?lez R, Ortiz-Rivera OJ, Bower B, Gorowski K, Windemuth A, Villagra D, Kocherla M, Seip RL, D'Agostino D, Vergara C, Rua?o G, Duconge J. Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J. 2010 Dec; 29(4):402-8.
Score: 0.082
-
Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Rua?o G. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis. 2009; 19(4):390-5.
Score: 0.072
-
Rodr?guez-Fern?ndez K, Reynaldo-Fern?ndez G, Reyes-Gonz?lez S, de Las Barreras C, Rodr?guez-Vera L, Vlaar C, Monbaliu JM, Stelzer T, Duconge J, Mangas-Sanjuan V. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model. Biomed Pharmacother. 2024 Jan; 170:115977.
Score: 0.051
-
Steiner HE, Carrion KC, Giles JB, Lima AR, Yee K, Sun X, Cavallari LH, Perera MA, Duconge J, Karnes JH. Local Ancestry-Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations. Clin Pharmacol Ther. 2023 03; 113(3):680-691.
Score: 0.047
-
Melin K, Moon JY, Qi Q, Hernandez-Suarez DF, Duconge J, Hua S, Gonzalez S, Zeng D, Kaplan RC. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. Pharmacogenomics. 2019 01; 20(2):75-83.
Score: 0.036
-
Claudio-Campos K, Duconge J, Cadilla CL, Rua?o G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metab Pers Ther. 2015 Jun; 30(2):87-105.
Score: 0.028
-
Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Rua?o G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 06; 411(17-18):1306-11.
Score: 0.020
-
Seip RL, Duconge J, Rua?o G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010 May; 6(3):409-24.
Score: 0.020
-
LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, Duconge J, Rua?o G. Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Conn Med. 2008 Aug; 72(7):399-403.
Score: 0.018